智翔金泰(688443.SH)：公司GR1803注射液系统性红斑狼疮适应症的临床试验申请获得批准

Core Viewpoint - The company, Zhixiang Jintai (688443.SH), has received approval from the National Medical Products Administration for the clinical trial of GR1803 injection for systemic lupus erythematosus (SLE) [1] Group 1: Product Development - GR1803 injection is a bispecific antibody drug developed by the company, targeting BCMA and CD3, classified as a Class 1 therapeutic biological product [1] - As of the announcement date, GR1803 injection is in the Phase II clinical trial stage for the indication of relapsed/refractory multiple myeloma [1] Group 2: Market Context - There are currently two imported BCMA×CD3 targeted antibody drugs conditionally approved for market in China, but there are no products targeting the same SLE indication available [1]